ArticleCancers2026
miRNA-Based Breast Cancer Subtyping Using AHALA Multi-Stage Classification Approach.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBreast cancers are heterogeneous in nature, including many molecular subtypes, each displaying varying characteristics in clinical outcomes as well as in responses to treatments. Subtyping requires absolute precision for the application of precision medicine; however, this is not an easy task, given the dimensionality as well as noise in miRNA expression profiles. Even though miRNAs display potential as a biological marker for subtyping breast cancers, feature selection and optimizing learning algorithms would help harness their potential as a diagnostic tool.
methodsWe propose the Adaptive Hill Climbing Artificial Lemming Algorithm (AHALA), a hybrid optimization framework that integrates the global search capability of the Artificial Lemming Algorithm with an adaptive hill-climbing local search strategy. Low-variance filtering and differential gene expression analysis were first applied to reduce dimensionality and enhance biological relevance. AHALA was then used to optimize deep neural network hyperparameters for miRNA-based multi-class breast cancer subtype classification. The method was validated using TCGA breast cancer miRNA expression data and benchmarked against state-of-the-art optimization algorithms using the CEC2021 test suite.
resultsAHALA had a high classification performance measure for each type of breast cancer with a mean accuracy of 95.74%, precision of 95.98%, recall of 95.74%, F1 measure of 95.74%, and AUC value of 0.9682. The new algorithm had superior convergence and significance compared with other optimization algorithms. Feature selection revealed miRNAs that belong to each subtype, such as hsa-miR-190b, hsa-miR-429, hsa-miR-505-3p, hsa-miR-3614-5p, and hsa-miR-935.
conclusionsThe AHALA framework offers a potent and efficient method of performing miRNA-based subtyping of breast cancer that integrates global exploration and local search to its advantage. Its high level of classification, stability, and ability to identify biologically important biomarkers mark this method as promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.